<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="417">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616976</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19 convalescent plasma</org_study_id>
    <nct_id>NCT04616976</nct_id>
  </id_info>
  <brief_title>COVID-19 With Convalescent Plasma</brief_title>
  <official_title>Efficiency of Convalescent Plasma Therapy in Management of Critically Ill Patients With COVID-19: a Matched Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To clarify the effects of convalescent plasma therapy on SARS-CoV-2 negative conversion rate&#xD;
      during hospital stay and 28-day mortality of severe and life-threatening COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days</time_frame>
    <description>the mortality from ICU admission to 28 days after admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 negative conversion rate</measure>
    <time_frame>up to 60 days</time_frame>
    <description>SARS-CoV-2 viral shedding</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>COVID-19 Convalescent Plasma Treatment</condition>
  <arm_group>
    <arm_group_label>convalescent plasma therapy group</arm_group_label>
    <description>the patients received convalescent plasma therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>the patients with similar situation without convalescent plasma therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>convalescent plasma</intervention_name>
    <description>convalescent plasma was get from the patients who recovery from COVID-19</description>
    <arm_group_label>convalescent plasma therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients with COVID-19 who were admitted to ICUs of the participating hospitals&#xD;
        between January 1 to February 29, 2020 were screened.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years of age;&#xD;
&#xD;
          2. laboratory-confirmed diagnosis of COVID-19;&#xD;
&#xD;
          3. respiratory failure requiring advanced respiratory support (i.e. high flow nasal&#xD;
             cannula[HFNC], noninvasive mechanical ventilation [NIV], and invasive mechanical&#xD;
             ventilation [IMV]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongda Hospital, Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Chun Pan</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>convalescent plasma therapy</keyword>
  <keyword>COVID-19</keyword>
  <keyword>mortality</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

